Alkermes shares fell 7.37% over the past week to US$48.99 after the company reported second-quarter 2026 results that showed higher revenue but a significantly lower quarterly net income. The most-followed narrative on Simply Wall St pegs fair value at US$47.69, suggesting the stock is about 3% overvalued, while the platform's own discounted cash flow model estimates fair value at US$99.55, roughly 51% above the current price. The bullish case rests on strong demand for proprietary neuroscience products Vivitrol, Aristada, and Lybalvi, driven by expanding diagnosis rates and greater patient access, though risks remain around orexin trial outcomes and product concentration. Longer-term returns remain robust, with a 90-day share price gain of 46.76% and a one-year total shareholder return of 84.52%.
Alkermes PlcMixed Q2 results with lower net income and analyst fair value debate weigh on shares.